QDEL Stock - QuidelOrtho Corporation
Unlock GoAI Insights for QDEL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.78B | $3.00B | $3.27B | $1.70B | $1.66B |
| Gross Profit | $1.29B | $1.49B | $1.94B | $1.28B | $1.35B |
| Gross Margin | 46.2% | 49.8% | 59.3% | 75.3% | 81.2% |
| Operating Income | $-1,960,900,000 | $139.10M | $843.70M | $906.00M | $1.06B |
| Net Income | $-2,052,000,000 | $-10,100,000 | $548.70M | $704.20M | $810.29M |
| Net Margin | -73.7% | -0.3% | 16.8% | 41.5% | 48.8% |
| EPS | $-30.54 | $-0.15 | $9.66 | $16.74 | $19.24 |
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| October 7th 2025 | Citigroup | Downgrade | Neutral | $33 |
| May 8th 2025 | Jefferies | Upgrade | Buy | $44 |
| December 11th 2024 | Citigroup | Upgrade | Buy | $50← $44 |
| December 10th 2024 | Jefferies | Initiation | Hold | $43 |
| September 19th 2024 | UBS | Resumed | Neutral | $50← $42 |
| September 5th 2024 | Craig Hallum | Upgrade | Buy | $57← $40 |
| March 4th 2024 | UBS | Downgrade | Sell | $42← $70 |
| February 14th 2024 | JP Morgan | Downgrade | Underweight | $37← $66 |
| December 11th 2023 | Citigroup | Downgrade | Neutral | $72← $95 |
| December 12th 2022 | Citigroup | Upgrade | Buy | $125← $90 |
| December 7th 2022 | RBC Capital Mkts | Initiation | Outperform | $125 |
| October 14th 2022 | UBS | Upgrade | Neutral | $86 |
| September 19th 2022 | Citigroup | Initiation | Neutral | $90 |
| July 20th 2022 | UBS | Initiation | Sell | $86 |
| June 17th 2022 | JP Morgan | Resumed | Neutral | $110← $80 |
Earnings History & Surprises
QDELEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $0.54 | — | — | — |
Q4 2025 | Nov 5, 2025 | $0.51 | $0.80 | +56.9% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $0.56 | $0.12 | -78.6% | ✗ MISS |
Q2 2025 | May 7, 2025 | $0.58 | $0.74 | +27.6% | ✓ BEAT |
Q1 2025 | Feb 12, 2025 | $0.55 | $0.63 | +14.5% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $0.31 | $0.85 | +174.2% | ✓ BEAT |
Q3 2024 | Jul 31, 2024 | $-0.21 | $-0.07 | +66.7% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $0.43 | $0.44 | +2.3% | ✓ BEAT |
Q1 2024 | Feb 13, 2024 | $2.02 | $1.17 | -42.1% | ✗ MISS |
Q4 2023 | Nov 1, 2023 | $0.45 | $0.90 | +100.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $0.25 | $0.26 | +4.0% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $1.40 | $1.80 | +28.6% | ✓ BEAT |
Q1 2023 | Feb 15, 2023 | $1.40 | $1.76 | +25.7% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $0.60 | $1.85 | +208.3% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $3.69 | $2.12 | -42.5% | ✗ MISS |
Q2 2022 | May 4, 2022 | $9.89 | $11.66 | +17.9% | ✓ BEAT |
Q1 2022 | Feb 17, 2022 | $5.61 | $7.29 | +29.9% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $3.52 | $5.36 | +52.3% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $1.20 | $0.75 | -37.5% | ✗ MISS |
Latest News
JP Morgan Maintains Underweight on QuidelOrtho, Lowers Price Target to $22
📉 NegativeUBS Maintains Neutral on QuidelOrtho, Raises Price Target to $31
➖ NeutralQDEL stock has given up its prior gain. QuidelOrtho shares were trading higher after the company reported better-than-expected Q3 financial results.
➖ NeutralQuidelOrtho shares are trading higher after the company reported better-than-expected Q3 financial results.
📈 PositiveQuidelOrtho Lowers FY2025 Adj EPS Guidance from $2.07-$2.57 to $2.00-$2.15 vs $2.22 Est; Narrows FY2025 Sales Guidance from $2.600B-$2.810B to $2.680B-$2.740B vs $2.702B Est
📉 NegativeQuidelOrtho Q3 Adj. EPS $0.80 Beats $0.46 Estimate, Sales $699.900M Beat $664.961M Estimate
📈 PositiveQuidelOrtho Receives FDA 510(k) Clearance For VITROS Immunodiagnostic Products hs Troponin I Assay
📈 PositiveReported Earlier, QuidelOrtho Highlights FDA-Approved MTS DAT Card And ORTHO VISION Platform Advancing Transfusion Medicine At AABB 2025
📈 PositiveCitigroup Downgrades QuidelOrtho to Neutral, Lowers Price Target to $33
📉 NegativeQuidelOrtho Expands QUICKVUE Portfolio With Launch Of Influenza Plus SARS Test Delivering Results In As Fast As 10 Minutes
📈 PositiveFrequently Asked Questions about QDEL
What is QDEL's current stock price?
What is the analyst price target for QDEL?
What sector is QuidelOrtho Corporation in?
What is QDEL's market cap?
Does QDEL pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to QDEL for comparison